|
1
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gonzalez H, Lema C, Kirken RA, Maldonado
RA, Varela-Ramirez A and Aguilera RJ: Arsenic-exposed keratinocytes
exhibit differential microRNAs expression profile; potential
implication of miR-21, miR-200a and miR-141 in melanoma pathway.
Clin Cancer Drugs. 2:138–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marin-Muller C, Li D, Bharadwaj U, Li M,
Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC and Yao Q: A
tumorigenic factor interactome connected through tumor suppressor
microRNA-198 in human pancreatic cancer. Clin Cancer Res.
19:5901–5913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ibarra I, Erlich Y, Muthuswamy SK,
Sachidanandam R and Hannon GJ: A role for microRNAs in maintenance
of mouse mammary epithelial progenitor cells. Genes Dev.
21:3238–3243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson CD, Esquela-Kerscher A, Stefani G,
Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J,
Shingara J, et al: The let-7 microRNA represses cell proliferation
pathways in human cells. Cancer Res. 15:7713–7722. 2007. View Article : Google Scholar
|
|
6
|
Kumar MS, Erkeland SJ, Pester RE, Chen CY,
Ebert MS, Sharp PA and Jacks T: Suppression of non-small cell lung
tumor development by the let-7 microRNA family. Proc Natl Acad Sci
USA. 105:3903–3908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barh D, Malhotra R, Ravi B and Sindhurani
P: MicroRNA let-7: An emerging next-generation cancer therapeutic.
Curr Oncol. 17:70–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sandercock J, Parmar MK, Torri V and Qian
W: First-line treatment for advanced ovarian cancer: Paclitaxel,
platinum and the evidence. Br J Cancer. 87:815–824. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R: Gynecologic Oncology Group: Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ledermann JA, Marth C, Carey MS, Birrer M,
Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, et al:
Role of molecular agents and targeted therapy in clinical trials
for women with ovarian cancer. Int J Gynecol Cancer. 21:763–770.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petrillo M, Zannoni GF, Beltrame L,
Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L,
Vizzielli G, Scambia G, et al: Identification of high-grade serous
ovarian cancer miRNA species associated with survival and drug
response in patients receiving neoadjuvant chemotherapy: A
retrospective longitudinal analysis using matched tumor biopsies.
Ann Oncol. 27:625–634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Zhang Y, Gao Y, Cui Y, Liu H, Li M
and Tian Y: Downregulation of HNF1 homeobox B is associated with
drug-resistance in ovarian cancer. Oncol Rep. 32:979–988. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye XM, Zhu HY, Bai WD, Wang T, Wang L,
Chen Y, Yang AG and Jia LT: Epigenetic silencing of miR-375 induces
trastuzumab resistance in HER2-positive breast cancer by targeting
IGF1R. BMC Cancer. 14:1342014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pedroza-Torres A, Fernández-Retana J,
Peralta-Zaragoza O, Jacobo-Herrera N, de Leon Cantu D, Cerna-Cortés
JF, Lopez-Camarillo C and Pérez-Plasencia C: A microRNA expression
signature for clinical response in locally advanced cervical
cancer. Gynecol Oncol. 142:557–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Çalışkan M, Güler H and Çetintaş Bozok V:
Current updates on microRNAs as regulators of chemoresistance.
Biomed Pharmacother. 95:1000–1012. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun YL, Patel A, Kumar P and Chen ZS: Role
of ABC transporters in cancer chemotherapy. Chin J Cancer.
31:51–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sui H, Cai GX, Pan SF, Deng WL, Wang YW,
Chen ZS, Cai SJ, Zhu HR and Li Q: miR-200c attenuates P-gp-mediated
MDR and metastasis by targeting JNK2/c-Jun signaling pathway in
colorectal cancer. Mol Cancer Ther. 13:3137–3151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samuel P, Pink RC, Brooks SA and Carter
DR: miRNAs and ovarian cancer: A miRiad of mechanisms to induce
cisplatin drug-resistance. Expert Rev Anticancer Ther. 16:57–70.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boyerinas B, Park SM, Murmann AE, Gwin K,
Montag AG, Zillhardt M, Hua YJ, Lengyel E and Peter ME: Let-7
modulates acquired resistance of ovarian cancer to Taxanes via
IMP-1-mediated stabilization of multidrug-resistance 1. Int J
Cancer. 130:1787–1797. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu K, Yang Y, Zhao J and Zhao S:
BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and
enhance apoptosis of human esophageal carcinoma cells by targeting
the drug transporter ABCC10. Cancer Lett. 371:125–133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao L, Ren Y, Tang H, Wang W, He Q, Sun
J, Zhou X and Wang A: Deregulation of the miR-222-ABCG2 regulatory
module in tongue squamous cell carcinoma contributes to
chemoresistance and enhanced migratory/invasive potential.
Oncotarget. 6:44538–44550. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma Y, Li X, Cheng S, Wei W and Li Y:
MicroRNA-106a confers cisplatin resistance in non-small cell lung
cancer A549 cells by targeting adenosine triphosphatase-binding
cassette A1. Mol Med Rep. 11:625–632. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feng R and Dong L: Knockdown of
microRNA-127 reverses adriamycin resistance via cell cycle arrest
and apoptosis sensitization in adriamycin-resistant human glioma
cells. Int J Clin Exp Pathol. 8:6107–6116. 2015.PubMed/NCBI
|
|
29
|
Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu
T, Hu T and Li J: MiR-27a modulates the MDR1/P-glycoprotein
expression by inhibiting FZD7/β-catenin pathway in hepatocellular
carcinoma cells. Cell Signal. 25:2693–2701. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Long QZ, Du YF, Liu XG, Li X and He DL:
miR-124 represses FZD5 to attenuate P-glycoprotein-mediated
chemo-resistance in renal cell carcinoma. Tumour Biol.
36:7017–7026. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng H, Liu Z, Liu T, Cai Y, Wang Y, Lin
S, Chen J, Wang J, Wang Z and Jiang B: Fas signaling promotes
chemoresistance in gastrointestinal cancer by up-regulating
P-glycoprotein. Oncotarget. 15:10763–10777. 2014.
|
|
32
|
Dong Z, Ren L, Lin L and Li J, Huang Y and
Li J: Effect of microRNA-21 on multidrug-resistance reversal in
A549/DDP human lung cancer cells. Mol Med Rep. 11:682–690. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wuerkenbieke D, Wang J, Li Y and Ma C:
miRNA-150 downregulation promotes pertuzumab resistance in ovarian
cancer cells via AKT activation. Arch Gynecol Obstet.
292:1109–1116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Mattos-Arruda L, Bottai G, Nuciforo PG,
Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Perez-Garcia J,
Masci G, Corsi F, et al: MicroRNA-21 links
epithelial-to-mesenchymal transition and inflammatory signals to
confer resistance to neoadjuvant trastuzumab and chemotherapy in
HER2-positive breast cancer patients. Oncotarget. 10:37269–37280.
2015.
|
|
35
|
Ma T, Yang L and Zhang J: miRNA-542-3p
downregulation promotes trastuzumab resistance in breast cancer
cells via AKT activation. Oncol Rep. 33:1215–1220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iorio MV, Casalini P, Piovan C, Di Leva G,
Merlo A, Triulzi T, Ménard S, Croce CM and Tagliabue E:
microRNA-205 regulates HER3 in human breast cancer. Cancer Res.
69:2195–2200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin K, Park S, Teo WW, Korangath P, Cho
SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, et al:
HOXB7 Is an ERα cofactor in the activation of HER2 and multiple ER
target genes leading to endocrine resistance. Cancer Discov.
5:944–959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim Y, Kim H, Park D, Han M, Lee H, Lee
YS, Choe J, Kim YM and Jeoung D: miR-217 and CAGE form feedback
loop and regulates the response to anti-cancer drugs through EGFR
and HER2. Oncotarget. 7:10297–10321. 2016.PubMed/NCBI
|
|
39
|
Xu Y, Huang J, Ma L, Shan J, Shen J, Yang
Z, Liu L, Luo Y, Yao C and Qian C: MicroRNA-122 confers sorafenib
resistance to hepatocellular carcinoma cells by targeting IGF-1R to
regulate RAS/RAF/ERK signaling pathways. Cancer Lett. 371:171–181.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z,
Li P, Zhang W, Wu H, Feng N, et al: miR-143 decreases prostate
cancer cells proliferation and migration and enhances their
sensitivity to docetaxel through suppression of KRAS. Mol Cell
Biochem. 350:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun Y, Chen C, Zhang P, Xie H, Hou L, Hui
Z, Xu Y, Du Q, Zhou X, Su B and Gao W: Reduced miR-3127-5p
expression promotes NSCLC proliferation/invasion and contributes to
dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep.
4:65272014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dai X, Jiang Y and Tan C: Let-7
sensitizes KRAS mutant tumor cells to chemotherapy. PLoS
One. 10:e01266532015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Amankwatia EB, Chakravarty P, Carey FA,
Weidlich S, Steele RJ, Munro AJ, Wolf CR and Smith G: MicroRNA-224
is associated with colorectal cancer progression and response to
5-fluorouracil-based chemotherapy by KRAS-dependent and
-independent mechanisms. Br J Cancer. 112:1480–1490. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
van Jaarsveld MT, van Kuijk PF, Boersma
AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM,
Verweij J and Wiemer EA: miR-634 restores drug sensitivity
in resistant ovarian cancer cells by targeting the Ras-MAPK
pathway. Mol Cancer. 14:1962015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ajduković J: HIF-1 - a big chapter in the
cancer tale. Exp Oncol. 38:9–12. 2016.PubMed/NCBI
|
|
46
|
Sajadimajd S, Yazdanparast R and Akram S:
Involvement of Numb-mediated HIF-1α inhibition in
anti-proliferative effect of PNA-antimiR-182 in
trastuzumab-sensitive and -resistant SKBR3 cells. Tumour Biol.
37:5413–5426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li
Y, Banerjee S, Padhye S and Sarkar FH: Hypoxia induced
aggressiveness of prostate cancer cells is linked with deregulated
expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.
PLoS One. 7:e437262012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan
C, Liu S and Zhang Y: MiR-338-3p inhibits hepatocarcinoma cells and
sensitizes these cells to sorafenib by targeting hypoxia-induced
factor 1α. PLoS One. 9:e1155652014. View Article : Google Scholar : PubMed/NCBI
|
